Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Oliver Grottke

Showing results (41-50 of 126) with videos related to

Pageof 13
Sort By:
Critical Care (London, England)|December 5, 2014
Porcine blood and surrogate markers do not prove benefit of aDabi-Fab. Authors' responseOliver Grottke, Joanne van Ryn, Henri M H Spronk, et al.
Transfusion|March 15, 2021
Response to Wirtz et al: The impact of blood product ratio and procoagulant therapy on the development of thromboembolic events in severely injured hemorrhaging trauma patientsThorsten Haas, Jeannie Callum, Oliver Grottke, et al.
Burns : Journal of the International Society for Burn Injuries|May 4, 2010
Glasgow Coma Scale and laboratory markers are superior to COHb in predicting CO intoxication severityGerrit Grieb, David Simons, Linda Schmitz, et al.
Thrombosis Journal|October 8, 2024
Monitoring the efficiency of reversal on anti-Xa direct oral anticoagulants using point-of-care viscoelastic testingLars Heubner, Oliver Grottke, Oliver Vicent, et al.
The American Journal of Emergency Medicine|October 7, 2016
Idarucizumab, a specific reversal agent for dabigatran: mode of action, pharmacokinetics and pharmacodynamics, and safety and efficacy in phase 1 subjectsPaul A Reilly, Joanne van Ryn, Oliver Grottke, et al.
The American Journal of Medicine|August 30, 2016
Idarucizumab, a Specific Reversal Agent for Dabigatran: Mode of Action, Pharmacokinetics and Pharmacodynamics, and Safety and Efficacy in Phase 1 SubjectsPaul A Reilly, Joanne van Ryn, Oliver Grottke, et al.
Critical Care (London, England)|April 20, 2010
Effects of different fibrinogen concentrations on blood loss and coagulation parameters in a pig model of coagulopathy with blunt liver injuryOliver Grottke, Till Braunschweig, Dietrich Henzler, et al.
Anesthesiology|June 11, 2019
Prothrombin Complex Concentrate-induced Disseminated Intravascular Coagulation Can Be Prevented by Coadministering Antithrombin in a Porcine Trauma ModelOliver Grottke, Markus Honickel, Till Braunschweig, et al.
Anesthesiology|May 29, 2014
Fibrinogen concentrate does not suppress endogenous fibrinogen synthesis in a 24-hour porcine trauma modelChristian Zentai, Till Braunschweig, Jonas Schnabel, et al.
Thrombosis and Haemostasis|January 9, 2015
Reversal of dabigatran anticoagulation ex vivo: Porcine study comparing prothrombin complex concentrates and idarucizumabMarkus Honickel, Stefanie Treutler, Joanne van Ryn, et al.
Pageof 13

Showing results (41-50 of 126) with videos related to

Sort By:
Pageof 13
Critical Care (London, England)|December 5, 2014
Porcine blood and surrogate markers do not prove benefit of aDabi-Fab. Authors' responseOliver Grottke, Joanne van Ryn, Henri M H Spronk, et al.
Transfusion|March 15, 2021
Response to Wirtz et al: The impact of blood product ratio and procoagulant therapy on the development of thromboembolic events in severely injured hemorrhaging trauma patientsThorsten Haas, Jeannie Callum, Oliver Grottke, et al.
Burns : Journal of the International Society for Burn Injuries|May 4, 2010
Glasgow Coma Scale and laboratory markers are superior to COHb in predicting CO intoxication severityGerrit Grieb, David Simons, Linda Schmitz, et al.
Thrombosis Journal|October 8, 2024
Monitoring the efficiency of reversal on anti-Xa direct oral anticoagulants using point-of-care viscoelastic testingLars Heubner, Oliver Grottke, Oliver Vicent, et al.
The American Journal of Emergency Medicine|October 7, 2016
Idarucizumab, a specific reversal agent for dabigatran: mode of action, pharmacokinetics and pharmacodynamics, and safety and efficacy in phase 1 subjectsPaul A Reilly, Joanne van Ryn, Oliver Grottke, et al.
The American Journal of Medicine|August 30, 2016
Idarucizumab, a Specific Reversal Agent for Dabigatran: Mode of Action, Pharmacokinetics and Pharmacodynamics, and Safety and Efficacy in Phase 1 SubjectsPaul A Reilly, Joanne van Ryn, Oliver Grottke, et al.
Critical Care (London, England)|April 20, 2010
Effects of different fibrinogen concentrations on blood loss and coagulation parameters in a pig model of coagulopathy with blunt liver injuryOliver Grottke, Till Braunschweig, Dietrich Henzler, et al.
Anesthesiology|June 11, 2019
Prothrombin Complex Concentrate-induced Disseminated Intravascular Coagulation Can Be Prevented by Coadministering Antithrombin in a Porcine Trauma ModelOliver Grottke, Markus Honickel, Till Braunschweig, et al.
Anesthesiology|May 29, 2014
Fibrinogen concentrate does not suppress endogenous fibrinogen synthesis in a 24-hour porcine trauma modelChristian Zentai, Till Braunschweig, Jonas Schnabel, et al.
Thrombosis and Haemostasis|January 9, 2015
Reversal of dabigatran anticoagulation ex vivo: Porcine study comparing prothrombin complex concentrates and idarucizumabMarkus Honickel, Stefanie Treutler, Joanne van Ryn, et al.
Pageof 13